The End of an Era: What the FDA's Move Away from Animal Testing Means for Biopharma

https://www.pharmasalmanac.com/articles/the-end-of-an-era-what-the-fdas-move-away-from-animal-testing-means-for-biopharma Professor Daniel Smith, Ph.D. discusses how the FDA’s move to phase out mandatory animal testing marks a pivotal shift toward human-relevant models in drug development, offering the potential for safer, faster, and more ethical therapies — if implemented with scientific rigor and global collaboration.